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6/j.bPeripheral blood stem cell (PBSC) products contain more T cells and monocytes when compared with bone
marrow (BM), leading to fewer bacterial and fungal infections. Cytomegelovirus (CMV) viral load and disease
as well as CMV-specific immune reconstitution were compared in patients enrolled in a randomized trial
comparing PSBC and BM transplantation. There was a higher rate of CMV infection and disease during
the first 100 days after transplantation among PBSC recipients (any antigenemia/DNAemia: PBSC, 63% vs
BM, 42%, P5 .04; CMV disease: PBSC, 17% vs BM, 4%, P5 .03). By 2 years, CMV disease rates were similar.
The early increase in CMV events correlated temporarily with lower CMV-specific CD41 T helper and
CD81 cytotoxic T lymphocyte function at 30 days after transplantation in PBSC recipients. By 3 months after
transplantation and thereafter, CMV-specific immune responses were similar between BM and PBSC recip-
ients. In conclusion, higher CMV infection and disease rates occurred in PBSC transplant recipients early af-
ter transplantation. These differences may be because of a transient delay in CMV-specific immune
reconstitution following PBSC transplantation.
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The use of peripheral blood stem cells (PBSC) for
transplantation improves survival in patients with
high-risk hematologic malignancies compared with
the use of bone marrow (BM) as a stem cell source
[1-3]. PBSC products from donors who receive
granulocyte-colony stimulating factor (G-CSF)
contain at least 1 log10 more T cells and monocytes
than BM, and absolute CD41 and CD81 lymphocyte
numbers are higher early after PBSC transplant [4-6].Hutchinson Cancer Research Center; 2University
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bmt.2011.05.010Overall, recipients of PBSC grafts have less frequent
severe infections, especially those of bacterial and
fungal etiologies [4].
The impact of PBSC transplantation on CMV-
specific immune reconstitution, clinical infection,
and disease is difficult to predict because of the unique
properties of CMV. Active CMV infection after trans-
plantation is controlled by CMV-specific CD41
T helper (Th) and CD81 cytotoxic T lymphocyte
(CTL) responses [7,8]. There is evidence for the
transfer of donor CMV-specific immunity with the
graft, because CMV seropositive recipients of seropos-
itive BM reconstitute CMV-specific T cell immunity
earlier than recipients of seronegative BM [9,10].
Although greater numbers of T cells are transferred
with PBSC grafts, CMV infects early and committed
hematopoietic progenitors [11,12], which may result
in transmission of a greater virus load with PBSC
products. Moreover, the BM and blood contain
different ratios of na€ıve, memory, and regulatory
T cell subsets that could influence the recovery of
functional CMV-specific T cells after transplantation
[13-15]. Thus, differences in the cellular composition
of BM and PBSC products may lead to different
rates of CMV infection after transplantation both by
influencing immune recovery and virus reactivation.
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been characterized by functional assays that measure
production of a single cytokine, such as interferon-
gamma (IFN-g), or by cytotoxicity or proliferation as-
says. Recently, multiparameter flow cytometry has
made it possible to simultaneously evaluate multiple
qualitative properties of T cells and enabled additional
characterization of T cell function based on the pro-
duction of combinations of cytokines [16,17]. In
a prior study, polyfunctional CD81 CMV-specific
T cells have been demonstrated to reconstitute differ-
ently inCMV-positive recipients of allogeneic hemato-
poietic cell transplantation (HCT) depending on the
serostatus of the donor, and patients with lower num-
bers of polyfunctional CD81 CMV-specific T cells
were taking antiviral drugs longer than patients with
a higher number of polyfunctional CD81 CMV-
specific T cells [18]. The purpose of this study was to
compare quantitative virologic outcomes and to under-
take exploratory analyses of CMV-specific T cell im-
mune reconstitution in transplant recipients who
participated in a randomized clinical trial of allogeneic
BM versus PBSC as a stem cell source for HCT.PATIENTS AND METHODS
Study Subjects
Patients participating in a multicenter randomized
trial comparing PBSC or BM as a stem cell source for
allogeneic transplant were analyzed for CMV infection
and CMV-specific immune reconstitution [2]. Viro-
logic analysis was done in all subjects who participated
in the randomized trial, whereas CMV immunity was
assessed in a subset of subjects at the Fred Hutchinson
Cancer Research Center (FHCRC) who signed an
additional consent form (Supplemental Figure S1).
Conditioning regimens and graft-verus-host disease
(GVHD) prophylaxis were administered as described
[19]. CMV immune reconstitution studies were per-
formed at 1 site (FHCRC) in a subset of patients
who agreed to provide additional blood samples.
Some of the data on qualitative immune reconstitution
have been previously published [4]. All participants
had an HLA-matched related donor and were .12
years of age. The study was approved by the institu-
tional review board at FHCRC, and all patients gave
informed consent.Virologic Testing
Pretransplantation CMV serostatus was deter-
mined by an ELISA at FHCRC and the Veterans
Administration Medical Center (Premier CMV IgG,
Meridian Diagnostic, Cincinnati, OH), indirect im-
munofluorescence assay at City of Hope National
Medical Center, Duarte, CA (Virgo; Hemagen Diag-nostics Inc., Columbia, MD), passive agglutination
test (Becton Dickinson, Meylan, France), and micro-
particle enzyme immunoassay (IMX Systems, Abbot
Laboratories, Abbot Park, IL) at Stanford University
Medical Center, Stanford, CA. All patients were pro-
spectively monitored for CMV reactivation by pp65
antigenemia and blood cultures (FHCRC, Veteran’s
Administration Hospital Seattle), plasma polymerase
chain reaction (PCR) for CMVDNA and shell vial cul-
tures (City of Hope National Medical Center), or
plasma PCR for CMV DNA (Stanford University
Medical Center). CMV pp65 antigenemia was quanti-
fied as the number of positive cells per slide; CMV
DNA was quantified as copy number/mL [4,20].Use of Acyclovir, Ganciclovir, Intravenous
Immunoglobulin, and CMV Seronegative Blood
Products
Acyclovir was given to herpes simplex virus (HSV)
seropositive individuals at a dose of 250 mg/m2 i.v.
twice daily from the start of conditioning until day
30 after transplantation. Documented HSV infections
were treated with acyclovir at a dose of 250 mg/m2 i.v.
3 times daily or 400 mg orally 5 times daily for 1 week.
Ganciclovir was administered for any pp65 antige-
nemia, shell vial cultures, or PCR positivity and con-
tinued until day 100 as described [21]. Intravenous
immunogloblin was administered to maintain IgG
level above 400 mg/mL [22]. CMV seronegative recip-
ients of a seropositive BM or PBSC product received
seronegative or filtered blood products throughout
the pre- and posttransplantation period [23].Definitions
CMV disease was defined as the identification of
a virus from 1 or more visceral sites (lung, gastrointes-
tinal tissue, liver) by culture or histology, or in the
blood alcohol level (BAL) by shell vial centrifugation
culture, conventional culture, or staining with direct
fluorescent antibodies combined with new or changing
pulmonary infiltrates on radiologic exam [24]. CMV
infection was defined as any pp65 antigenemia or
plasma PCR positivity. CMV viremia was defined as
detection of CMV by rapid or conventional culture.
Acute and chronic GVHD (aGVHD, cGVHD) were
defined as described [25].CMV-Specific Immune Reconstitution
CMV immune reconstitution studies were done on
fresh (LDA and CTL assay) or cryopreserved periph-
eral blood mononuclear cells (PBMC) (intracellular
cytokine analysis); experiments using cryopreserved
cells were performed only in the CMVD1/R1 subset.
Denominators for each test differ because of availabil-
ity of cells (Supplemental Figure S1).
Table 1. Patient Characteristics*
Characteristic
BM PBSC
N 5 91 N 5 81
Recipient age (median, range) 42 (12-55) 42 (15-55)
Recipient sex (male/female) 62/29 56/25
Underlying disease status
Less advanced 51 (56%) 41 (51%)
More advanced 40 (44%) 40 (49%)
CMV serostatus
Recipient positive/donor positive 36 (40%) 29 (36%)
Recipient positive/donor negative 14 (15%) 17 (21%)
Recipient negative/donor positive 14 (15%) 15 (18%)
Recipient negative/donor negative 27 (30%) 20 (25%)
Acute GVHD by day 100
Grade 2-4 64% 57%
Grade 3-4 12% 15%
Chronic clinical extensive GVHD at 3
years
52% 63%
GVHD indicates graft-versus-host disease; CMV, cytomegalovirus; BM,
bone marrow; PBSC, peripheral blood stem cell.
*Analysis of CMV virologic endpoints was performed in all randomized
patients; analysis ofCMV immune reconstitutionwas performed in a sub-
set that agreed to additional blood draws and skin biopsies (Figure S1).
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Short-term CMV-specific CTL lines were ex-
panded in vitro according to previously described
methods [10]. Briefly, fibroblast lines were established
from skin biopsies obtained from the recipient or the
HLA identical donor. Recipient PBMC were stimu-
lated twice 7 days apart with fibroblasts infected
with CMV AD169, and cytolytic activity against
HLA-identical and HLA class I-mismatched CMV-
infected and mock-infected fibroblasts was then
measured using a 5-hour chromium release assay.
Specific lysis was calculated according to the standard
formula as described [10]. A positive CTL response
was defined as lysis of HLA-identical CMV-infected
targets at a level at least 10% greater than lysis of
HLA-identical mock-infected and HLA class I mis-
matched CMV- and mock-infected targets.
Limiting dilution assay (LDA)
The frequency of CMV-specific T cells was deter-
mined by LDA using methods and calculations previ-
ously described [26]. Briefly, fresh PBMC were plated
in 8 serial 2-fold dilutions starting from 105 cells per
well in the presence of CMV antigen (24 replicates)
or mock antigen (12 replicates). Each well also re-
ceived 104 gamma irradiated (3300 rad) autologous
PBMC to serve as antigen presenting cells. After
5 days, the wells were pulsed with 0.6 mCi 3H thymi-
dine and harvested after 18-24 hours. Wells were
scored positive if the mean 3H thymidine incorpora-
tion was .3 times that in the corresponding control
wells. Precursor frequencies were calculated by the
chi-square minimization method [27] with a computer
program [28] written by L. Sirinek (provided by C. Or-
osz, both from Ohio State University, Columbus,
OH). To compensate for differences between CD41
and total T cells between PBSC and BM recipients, re-
sults were normalized either with absolute lymphocyte
count and to calculate the number of CMV-specific
CD41 T cells/L or by the number of CMV-specific
CD41 T cells per 1  106 PBMC [4].
Intracellular cytokine staining
Cryopreserved PBMC were thawed and rested
overnight. The following day, PBMC were incubated
with anti-CD107a PECy5 Ab for 10 minutes, followed
by the addition of the costimulatory antibodies anti-
CD28 (1 mg/mL; Becton Dickinson, San Jose, CA)
and anti-CD49d (1 mg/mL). Cells were then stimu-
lated with CMVpp65 protein (2 mg/mL), Staphylococcus
aureus enterotoxin B (0.05 mg/mL), or medium for 6
hours at 37C and 5% CO2. Brefeldin A (10 mg/mL,
Sigma)/Golgi stop (Becton Dickinson, San Jose, CA,
USA) was added during the last 4 hours of incubation.
Samples were held overnight at 4C and then stained
for flow cytometric analysis the following day.After incubation with EDTA (20 mM), samples
were incubated successively with FACSlyse and
FACSperm(BDBiosciences&Pharmingen, SanDiego,
CA), washed, and then incubated for 30 minutes in the
dark at room temperature with a cocktail of antibodies
consisting of CD3 ECD (Beckman Coulter, Brea,
CA), CD8 PerCypCy 5.5 (BD Biosciences & Pharmin-
gen, San Diego, CA), IFN-g APC,MIP-1b PE, and tu-
mor necrosis factor-alpha (TNF-a) A700 (BD
Bioscience& Pharmingen, San Jose, CA). Last, samples
were fixed with 1% paraformaldehyde and cell acquisi-
tion (range 100,000 to 400,000) was done on an LSRII
flow cytometer. Appropriate single color compensation
and fluorescence minus 1 controls were run. Data were
initially analyzed with FlowJo Version 8.8.6, and then
further with PESTLE version 1.6.2 and SPICE version
5.0 (Simplified Presentation of Incredibly Complex
Evaluations) software provided by M. Roederer of the
National Institute of Allergy and Infectious Diseases.
Statistical Analysis
Time to CMV events was assessed by cumulative
incidence curves and the log-rank test. The Student
t test, Fisher exact test, and the Wilcoxon matched
pairs test were done as appropriate on Prism software
v5.0 (GraphPad Software, LA Jolla, CA).RESULTS
Study Subjects
A summary of relevant patient characteristics
is shown in Table 1, and additional characteristics
have been published elsewhere [4] (Supplemental
Figure S1). The 2 study arms (BM and PBSC) were
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patients who were studied for CMV-specific T cell im-
mune reconstitution was also balanced between the
study arms.
CMV Infection and Disease
Seropositive recipients
The incidence of pp65 antigenemia or CMVDNA
at any level before day 100 was higher in PBSC than in
BM recipients (P5 .04) (Figure 1A). There was no sta-
tistically significant difference between the 2 groups in
the incidence of high (.100 cells/slide or .100,000
copies/mL) viral load by PCR or antigenemia
(Figure 1B). CMV disease before day 100 was signifi-
cantly higher in CMV seropositive recipients of
PBSC (P 5 .03) compared with BM (Figure 1C).
There was no difference in virologic parameters rela-
tive to donor CMV serostatus (Table 2).
Seronegative recipients
There was a trend toward more primary infection
in patients who received PBSC than those who re-
ceived BM (Table 2). In seronegative recipients of
seronegative PBSC or BM, infection rates were low
and not statistically different (Table 2). There was no
CMV disease among seronegative recipients.
Time to cessation of antigenemia after
ganciclovir early treatment
There was no statistically significant difference
based on transplant type in the time to cessation of
pp65 antigenemia or PCR positivity after the start of
preemptive therapy in the subset of HCRC patients
(data not shown).
Analysis of CMV-Specific TCells in Donor PBMC
Before and in the PBSC Product After G-CSF
Treatment
Wemeasured the number of CMV-specific T cells
by LDA in the peripheral blood of PBSC donors before
G-CSF treatment and in the stem product after G-CSF
treatment. Interestingly, there were significantly fewer
(P 5 .04) CMV-specific Th cells after G-CSF treat-
ment (Figure 2). In addition, phytohemagglutin
(PHA) stimulation also resulted in significantly less
lymphocyte proliferation (P5 .005,Wilcoxonmatched
pairs test) in the post-G-CSF stem cell product com-
pared with pre-GCSF PBMC (data not shown). These
results suggest that G-CSFmobilization either resulted
in a decline in the number of CMV-specific CD41 T
helper cells in the stem cell product or altered their abil-
ity to respond to antigen stimulation, either of which
could contribute to delayed recovery of CMV-specific
immune responses observed in PBSC recipients early
after transplantation.Analysis of CMV-Specific Immune
Reconstitution in BM and PBSC Recipients
CD81 and CD41CMV-specific T cell reconstitu-
tion was evaluated at days 30, 80, 180, and 365 post-
transplantation by cytotoxicity assay (CTL) and
LDA. In addition, based on immunocompetent do-
nors’ (N 5 41) LDA results, $33 (25th percentile)
CMV-specific CD41 T cells per 1  106 PBMC was
established as a threshold for LDA (range: 13.91-
6422.61, median: 76.92, 75th percentile 258.61 per
1  106 PBMC).
The proportion of BM recipients who exhibited
CMV-specific lysis .10% at day 30 after transplanta-
tion was higher than in PBSC recipients (Figure 3A).
This difference did not reach statistical significance,
however (P5 0.17, Fisher exact test), and the numerical
difference was no longer present by day 80 after trans-
plantation. A trend toward a higher proportion (P 5
.24, Fisher exact test) of patients with $33 CMV-
specific CD41 T cells was documented by LDA at
day 30 and day 80 in BM compared with PBSC recipi-
ents (Figure 3B).Collectively, these results suggest that
despite the higher T cell dose administered to PBSC
recipients, CMV-specific T cell responses as measured
by T cell proliferation and cytolytic function assays
may have been enhanced in BM recipients.Cytokine Production and Degranulation by
CMV-Specific CD81 T Cells after PBSC and BM
Transplantation
We used multiparameter flow cytometry com-
bined with cytokine staining to directly evaluate the
presence and function of CMV-specific CD81 T cells
in blood samples that were obtained at days 30 and 80
posttransplantation in a subset of PBSC and BM recip-
ients (D1/R1) with available PBMC. Cryopreserved
PBMC were thawed, stimulated with CMVpp65 anti-
gen, and then evaluated for IFN-g, MIP-1b, TNF-a,
and CD107a expression by intracellular staining. No
statistical differences were documented in the absolute
number of CMV-specific CD81 T cells between BM
and PBSC recipients at either day 30 or 80 posttrans-
plantation (Figure 4A and B).Comparison of Polyfunctional CMV-Specific
CD81 T Cells in BM and PBSC Recipients
Analyses of intracellular cytokine data using
PESTLE and SPICE software allows for the further
characterization of T cells as polyfunctional based on
concurrent expression of different combinations of
cytokines. Sixteen combinations were possible for
CD81T cells based on the evaluation of 4 parameters:
IFN-g, MIP-1b, TNF-a, and CD107a in this study.
We grouped polyfunctional T cells as T cells positive
for 4, 3, 2, or only 1 of these markers.
Figure 1. Differences in CMV infection and disease between BM and PBSC recipients. Time to positive antigenemia or PCR positivity at any level (A),
antigenemia .100 positive cells per slide or CMV DNA .100,000 copies/mL plasma (B), and CMV disease (C) among CMV seropositive recipients
(BM, n 5 50; PBSC, n 5 46).
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portion of the absolute number of polyfunctional
CMV-specific CD81 T cells/L positive for 2, 3, and
4 markers in BM was 18%, 20%, and 27% comparedwith 6%, 8%, and 8%, respectively, for PBSC recipi-
ents. Single-cytokine-producing T cells encompassed
the largest proportion of T cells in PBSC recipients
at day 30 posttransplantation, and this fraction was
Table 2. Incidence of CMV Infection and Disease before 2 Years by CMV Serostatus
Manifestation of CMV
BM PBSC
R+
N 5 50
D+/R+
N 5 36
D2/R+
N 5 14
D+/R2
N 5 13
D2/R2
N 5 27
R+
N 5 46
D+/R+
N 5 29
D2/R+
N 5 17
D+/R2
N 5 15
D2/R2
N 5 20
pp65 antigenemia or CMV DNA in
plasma (day 100)
Any level 42%* 42% 43% 0† 7% 63%* 59% 71% 19%† 10%
>10 + cells/slides or >1000 copies/mL 24% 25% 21% 0 0 26% 31% 18% 19% 5%
>50 + cells/slides or >10,000 copies/mL 16% 17% 14% 0 0 9% 14% 0 0 0%
CMV disease
 Day 100 after HCT 4%‡ 3% 7% 0 0 17%‡ 14% 24% 0 0
 Two years after HCT 8% 6% 14% 0 0 20% 17% 24% 6% 0
R indicates recipient; D, donor; HCT, hematopoietic cell transplantation; CMV, cytomegalovirus; BM, bone marrow; PBSC, peripheral blood stem cell.
*P 5 .04, between BM and PBSC recipients who are R+.
†P 5 .03, between BM and PBSC recipients who are D+/R2.
‡P 5 .03, between BM and PBSC recipients who are R+.
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cytokine-producing CD81 T cells per liter in BM re-
cipients (PBSC, 77% [6.1  107 cells/L] vs BM,
36% [6.8  106 cells/L] (P 5 .006, Student test)
(Figure 4C). However, by day 80, the proportion of
polyfunctional CMV-specific CD81 T cells was simi-
lar between BM and PBSC recipients (Figure 4D).
Beyond single-cytokine-producing T cells, there
was no difference in the absolute number of CMV-
specificCD81Tcells/L positive for 2, 3, and 4markers
between BM and PBSC recipients (data not shown).
This lack of quantitative difference prompted us to
evaluate of the quality of T cell response rather than
the quantity alone.
We analyzed the median fluorescence intensities
(MFI) of each marker in quadruple-positive CMV-
specific CD81 T cells to look for any differences in
the capacity to produce cytokines or degranulate
[29,30]. At day 30, we documented a trend toward
higher MFI values for IFN-g, MIP-1b, and CD107a,
but not TNF-a, in BM compared with PBSC
recipients. These differences were not significant,
however, and were lost by day 80 (data not shown).Figure 2. Effect of G-CSF on donor peripheral blood mononuclear
cells (PBMC) and stem cell (SC) product. (A) Represents the number
of CMV-specific CD41 T helper cells in donor PBMC and the stem
cell product, pre- and post-G-CSF treatment (n 5 12). P value is from
the Wilcoxon matched pairs test.We further analyzed the effect of polyfunctionality
on the MFI values of IFN-g based on the degree of
decreasing polyfunctionality of CMV-specific CD81
T cells by the loss of 1 marker (TNF-a, MIP-1b, and
CD107a). At day 30, the MFI values of IFN-g in
CMV-specific CD81 T cells from BM recipients
decreased along with the loss of polyfunctionality
compared with CMV-specific CD81 T cells from
PBSC recipients, which increased along with the loss
of polyfunctionality (Figure 4E). At day 80,MFI values
of IFN-g in CMV-specific CD81 T cells from both
BMandPBSC recipients decreasedwith the loss of pol-
yfunctionality (Figure 4F). Although not statistically
significant, these differences in MFI values hint at the
complexity of polyfunctional profiles in CMV-
specific CD81 T cells isolated from BM and PBSC
recipients. Overall, these observations support the
notion that a delay in CMV immune reconstitution
early posttransplantation in PBSC recipients is tran-
sient and associated not just with T cell quantity, but
rather with the quality of T response.Comparison of Polyfunctional T Cells between
Patients with No Antigenemia and Those with
Antigenemia
To determine the potential functional relevance of
mono- versus polyfunctional CMV-specific T cells, we
further compared the absolute number of polyfunctional
CMV-specific CD81 T cells at day 30 in patients
with and without subsequent antigenemia, regardless
of transplant type. In this analysis, we defined polyfunc-
tional T cells as any T cell positive for 2 or more
markers. In patients with no antigenemia by day 80,
the average number of polyfunctional T cells at day 30
was 2.14  107/L compared with 4.6  106/L in
patients with any antigenemia (P 5 .09, Student test)
(Figure 5A). In addition, a similar trendwas documented
between the average numbers of CMV-specific CD41
T cells in patients with no antigenemia (1.8  105
cells/L) compared with those with any antigenemia
Figure 3. Differences in CMV-specific T cell immune reconstitution between BM and PBSC recipients. (A) Represents the proportion of patients with
CMV-specific cell lysis greater than 10% between BM and PBSC recipients at day 30 (BM, n 5 8; PBSC, n 5 8), 80 (BM, n 5 9; PBSC, n 5 8), 180
(BM, n 5 6; PBSC, n 5 7), and 365 (BM, n 5 6; PBSC, n 5 4) posttransplantation. (B) Represents the proportion of patients with $33 CMV-specific
CD41 T cells per 106 PBMC as determined by limiting dilution assay at day 30, 80, 180, and 365 (BM, n 5 22; PBSC, n 5 22) posttransplantation.
72 Biol Blood Marrow Transplant 18:66-75, 2012A. Guerrero et al.(5.7  103 cells/L) by LDA analysis (P5 .3, Student t
test) (Figure 4B). These results suggest that regardless
of stem cell source, polyfunctional T cells are
associated with protection from CMV reactivation.DISCUSSION
In this study, we compared the temporal pattern of
CMV reactivation, CMV disease, and CMV-specific
immune reconstitution in patients enrolled in a ran-
domized trial of BM or PBSC as a graft source for
transplantation. We observed a higher incidence of
CMV infection andCMVdisease early after transplan-
tation in PBSC recipients. We hypothesized that the
differences in virologic data resulted from differences
in the reconstitution of a CMV-specific immune re-
sponse between BM and PBSC recipients after trans-
plantation.
In contrast to the findings in nonrandomized stud-
ies, we observed a higher rate of CMV infection and
disease in PBSC recipients. Walker et al. [31] showed
a delay in the development of CMV antigenemia in
PBSC recipients, but no overall difference in the
incidence of antigenemia between BM and PBSC
recipients. Trenschel et al. [32] reported a similar
incidence of CMV antigenemia, but less persistent
antigenemia and a trend toward less CMV disease in
PBSC recipients. On the other hand, Manteiga et al.
[33] found higher rates of CMV infection and disease
in PBSC recipients, which is in agreement with our
findings. Possible reasons for these differences include
different proportions of unrelated donors, use of T cell
depletion in some studies, high-dose acyclovir prophy-
laxis, and differences in the patient populations in
terms of age, disease status, and prior therapy across
these studies.
Our results stem from a randomized study
with a well-balanced distribution of pre- and
posttransplantation risk factors for CMV (Table 1).The increase in early CMV reactivation that we ob-
served in PBSC recipients was not explained by earlier
onset of GVHD or an increased use of corticosteroids.
Therefore, it is theoretically possible that the increase
of CMV reactivation resulted from higher rates of
CMV transfer in the donor PBSC product, perhaps
within granulocytes or hematopoietic progenitors.
Granulocyte transfusions have been associated with
an increased risk of CMV infection [34-36]. An
alternative and not mutually exclusive explanation for
the differences in CMV infection and disease is that
G-CSF treatment promotes the emergence of CMV
from latency, either by direct effects of G-CSF
signaling in latently infected cells or by reducing the
ability of T cells to limit reactivation [37]. Heightened
transfer of CMV is partially supported by a trend to-
ward a higher transmission rate in the CMV D1/R2
setting, but not among R1 patients (Table 2). How-
ever, the number of D1/R2 patients in this cohort
was too small and the CMV event rate in the D1/
R2 BM recipients was unusually low [38], making it
difficult to test this possibility statistically. No defini-
tive conclusions can be drawn, and larger studies are
needed to more thoroughly examine this question.
Mielcarek et al. [39,40] proposed that monocytes in
G-CSF-treated PBMC are capable of inhibiting T cell
proliferation, possibly resulting in lower GVHD
following HSCT. We did not find any association
between the number of monocytes and CMV-specific
CD41T cells after G-CSF treatment (data not shown).
We did observe, however, that G-CSF treatment
lowered the number of CMV-specific CD41 T cells
in the donor product detected by a functional assay
that requires T cell proliferation. Our proposal that
a deficiency of functional CMV-specific CD41 T cells
in PBSC contributes to the delayed recovery of immu-
nity in PBSC recipients is supported by work done by
Pourgheysari et al. [41], who demonstrated that early
posttransplantation deficiencies in CMV-specific
CD41 T cells are associated with a high risk of viral
Figure 4. Differences in polyfunctional CMV-specific CD81 T cells between BM and PBSC recipients. (A, B) Represents the absolute number of CD81
T cells in BM (n 5 7†) and PBSC (n 5 6†) recipients positive for CD107a, IFN-g, MIP-1b, and TNF-a at day 30 and day 80 posttransplantation. (C, D)
Represents the absolute proportion of polyfunctional CMV-specific CD81 T cells within BM and PBSC recipients at day 30 and day 80. (E, F) Represents
the MFI of IFN-g based on the degree of decreasing polyfunctionality of CMV-specific CD81 T cells by the loss of one marker (CD107a, MIP-1b, and
TNF-a). Polyfunctional T cells grouped by T cells positive for 1, 2, 3, or 4 of the markers based on the 16 possible combinations according to SPICE. The
P value is a result of the Student test. Bars represent the mean value within each group, and error bars are the standard error of the mean.
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(90%of thepatients in that studywerePBSCrecipients).
ImpairmentofbothCD41 andCD81Tcells before100
days after transplantation was also associated with late
viral reactivation in that study [41]. A plausible explana-
tion for the virologic differences observed in our study is
impairment of the quantity or quality of CMV-specific
T cells early after PBSC transplantation. At day 30 post-
transplantation in PBSC recipients, we documented (1)
fewer CMV-specific CD41 T cells, (2) less CMV-
specific cell lysis, (3) a greater proportion of CD81
CMV-specific T cells that mainly produced
a single cytokine, and (4) a lower proportion ofpolyfunctional T cells together with a lower capacity
for cytokine production and cytotoxicity.
The correlation of polyfunctional T cells with con-
trol of viral infection was first studied in HIV infection
[42]. Betts et al. [42] demonstrated that individuals with
nonprogressive HIV infection maintain polyfunctional
HIV-specific CD81 T cells that correlate inversely
with viral load. Similarly, Darrah et al. [30] demon-
strated that protection against Leishmania major infec-
tion in mice is associated with polyfunctional CD41
T cells with enhanced effector function. Polyfunctional
T cells are also known to have a higher capacity for
cytokine production and cytotoxicity compared with
Figure 5. Comparison of CMV-specific polyfunctional CD81 T cells between patients with no antigenemia and those with antigenemia. (A) Represents
the number of polyfunctional T cells/L at day 30 in patients with no (n5 5†) and any subsequent antigenemia (n5 7†) at day 30 regardless of stem cell
source. (B) Represents the number of CMV-specific CD4 T cells/L (by LDA) at day 30 in patients without (n 5 20†) and any subsequent antigenemia
(n5 11†). †Includes patients who were eligible for randomization but did not participate in the randomized trial. Bars represent the mean value within
each group, and error bars are the standard error of the mean.
74 Biol Blood Marrow Transplant 18:66-75, 2012A. Guerrero et al.single-cytokine-producing T cells [29].When we com-
pared CMV-specific T cell function between patients
with no antigenemia versus those with antigenemia,
we found a trend toward a larger number of polyfunc-
tional T cells in patients with no antigenemia. These
observations further support the association of poly-
functional T cells with protective immunity.
It is important to recognize that our polyfunctional
studies were done on a small number of patients
because of limited sample availability. Because of the
resulting low statistical power for many of the compar-
isons, we primarily noted statistical trends. Our find-
ings are consistent, however, with a prior study by
Lilleri et al. [43], who also found that polyfunctional
CMV-specific T cells producing IFN-g and IL-2
were associated with protection. In addition, the in-
crease of MFI values of IFN-g, with decreased CMV-
specific CD81 polyfunctionality in PBSC recipients
at day 30 aligns with the work of Krol et al. [44], who
suggested that production of IFN-g alone may be
a sign of T cell exhaustion during viral infection. We
recently showed, using CMV-specific tetramers, that
HCT patients with $7 positive tetramer cells/mL in
at least 1 blood sample before day 65 posttransplanta-
tion were statistically protected from CMV infection
[45], although the protection was not complete. Poly-
functional T cells may provide an improved functional
marker of protection, but larger prospective studies are
needed to demonstrate this conclusively.
In conclusion, PBSC recipients early after post-
transplantation demonstrate more CMV reactivation
and disease. These findings appear to be temporarily
related to a transient delay in CMV-specific immune
reconstitution, perhaps as a consequence of G-CSF
treatment.Whether T cell polyfunctionality is a defin-
itive marker of protection from CMV reactivation
requires larger prospective studies.ACKNOWLEDGMENTS
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